Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Journal
Clinical lung cancer
Journal Volume
23
Journal Issue
8
Pages
720
Date Issued
2022-12
Author(s)
Ahn, Myung J
Kim, Hye R
Han, Ji-Yu
Li, Jacky Yu-Chung
Hochmair, Maximilian J
Chang, Gee-Chen
Delmonte, Angelo
Lee, Ki H
Campelo, Rosario G
Gridelli, Cesare
Spira, Alexander I
Califano, Raffaele
Griesinger, Frank
Ghosh, Sharmistha
Felip, Enriqueta
Kim, Dong-Wan
Liu, Yuyin
Zhang, Pingkuan
Popat, Sanjay
Camidge, D Ross
Abstract
Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial.
Subjects
ALK TKI-naive; Anaplastic lymphoma kinase; Clinical trial; First line; Tyrosine kinase inhibitor
Publisher
CIG MEDIA GROUP, LP
Type
journal article